{"id":"W2979765136","doi":"10.1182/blood.v120.21.2745.2745","title":"Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; CD30; Oncology; Population; Phases of clinical research; Clinical endpoint; Lymphoma; Surgery; Chemotherapy; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002296698,0.0006916285,0.001843965,0.0002799642,0.0004594346,0.0006166165,0.0004672252,0.0008155008,0.001829459],"category_scores_gemma":[0.001461432,0.0003712809,0.0007831458,0.0002472963,0.0004338078,0.0005753754,0.0003493903,0.002218598,0.0004886961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000702071,"about_ca_system_score_gemma":0.0007718542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000778195,"about_ca_topic_score_gemma":0.001314958,"domain_scores_codex":[0.9994159,0.000253047,0.00003812125,0.0001036984,0.00007445479,0.0001148114],"domain_scores_gemma":[0.9986174,0.0002974068,0.0003100934,0.0001143449,0.00009613193,0.0005645371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5693545,0.07254697,0.06754028,0.001088734,0.002833139,0.001154449,0.0009308874,0.003167475,0.07290325,0.0001693129,0.004254676,0.2040564],"study_design_scores_gemma":[0.2126648,0.6334938,0.1412514,0.00005451529,0.001150059,0.0009483182,0.0001218483,0.001759965,0.004788082,0.0001354102,0.003592786,0.00003903515],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996472,0.001481333,0.0001809573,0.0001112939,0.00003101763,0.0005696768,0.0003756828,0.00003238586,0.0007456893],"genre_scores_gemma":[0.9965308,0.0005122364,0.0003102214,0.0003087469,0.00005875321,0.0005223342,0.001126277,0.000007767974,0.0006228578],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002296698,"threshold_uncertainty_score":0.01214623,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02448286984413069,"score_gpt":0.2785730313743936,"score_spread":0.2540901615302629,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}